AU2001291911A1 - Novel antibody, immunoassay and method for prostate cancer detection - Google Patents

Novel antibody, immunoassay and method for prostate cancer detection

Info

Publication number
AU2001291911A1
AU2001291911A1 AU2001291911A AU9191101A AU2001291911A1 AU 2001291911 A1 AU2001291911 A1 AU 2001291911A1 AU 2001291911 A AU2001291911 A AU 2001291911A AU 9191101 A AU9191101 A AU 9191101A AU 2001291911 A1 AU2001291911 A1 AU 2001291911A1
Authority
AU
Australia
Prior art keywords
pca
patients
psa
antibody
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001291911A
Other languages
English (en)
Inventor
Hans Lilja
Timo Lovgren
Pauliina Niemela
Kim Pettersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arctic Partners Oy AB
Original Assignee
Arctic Partners Oy AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arctic Partners Oy AB filed Critical Arctic Partners Oy AB
Publication of AU2001291911A1 publication Critical patent/AU2001291911A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001291911A 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection Abandoned AU2001291911A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20002127 2000-09-27
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
PCT/FI2001/000834 WO2002027323A1 (fr) 2000-09-27 2001-09-26 Nouvel anticorps, dosage immunologique et methode de detection du cancer de la prostate

Publications (1)

Publication Number Publication Date
AU2001291911A1 true AU2001291911A1 (en) 2002-04-08

Family

ID=8559172

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001291911A Abandoned AU2001291911A1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection

Country Status (9)

Country Link
US (1) US7872104B2 (fr)
EP (1) EP1320756B1 (fr)
JP (1) JP5254517B2 (fr)
AT (1) ATE425460T1 (fr)
AU (1) AU2001291911A1 (fr)
DE (1) DE60137949D1 (fr)
ES (1) ES2322432T3 (fr)
FI (1) FI20002127A0 (fr)
WO (1) WO2002027323A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
CA2853705C (fr) * 2011-10-25 2021-10-12 Memorial Sloan-Kettering Cancer Center Anticorps anti-psa libres en tant que produits de diagnostic, de pronostic et therapeutiques pour le cancer de la prostate
EP2771037B1 (fr) 2011-10-28 2016-08-03 Fredax AB Agents thérapeutiques et utilisations de ceux-ci
BR112014021776B1 (pt) * 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
JP6312141B2 (ja) * 2012-03-30 2018-04-18 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
KR102442738B1 (ko) 2013-11-19 2022-09-15 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
SG10201808585TA (en) * 2014-03-28 2018-11-29 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
EP3922265A1 (fr) * 2015-10-05 2021-12-15 Fredax AB Anticorps humanisés anti psa (5a10)
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635575A1 (fr) * 1993-07-22 1995-01-25 Wallac Oy Anticorps monoclonales contre les épitopes trouvés dans l'antigène spécifique de la prostate à l'état libre mais pas à l'état complexé avec l'alpha-1-antichymotrypsine
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
JPH10150999A (ja) * 1996-11-22 1998-06-09 Eiken Chem Co Ltd ヒト前立腺特異抗原−α１−アンチキモトリプシン複合体に対するモノクローナル抗体及びそれを用いたヒト前立腺特異抗原−α１−アンチキモトリプシン複合体の免疫学的検出法
US5858685A (en) * 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
CA2286090C (fr) * 1997-04-30 2013-01-08 Hybritech Incorporated Formes d'antigene a specificite prostatique (asp) et leurs procedes de detection
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone

Also Published As

Publication number Publication date
US7872104B2 (en) 2011-01-18
WO2002027323A1 (fr) 2002-04-04
ATE425460T1 (de) 2009-03-15
US20040101914A1 (en) 2004-05-27
DE60137949D1 (de) 2009-04-23
EP1320756B1 (fr) 2009-03-11
EP1320756A1 (fr) 2003-06-25
JP5254517B2 (ja) 2013-08-07
ES2322432T3 (es) 2009-06-22
FI20002127A0 (fi) 2000-09-27
JP2004509934A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
Mikolajczyk et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
Mönig et al. Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma
Chenard et al. High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma
Fritzsche et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer
Chan et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
AU2001291911A1 (en) Novel antibody, immunoassay and method for prostate cancer detection
WO2006119155A3 (fr) Profilage diagnostique d'anticorps seriques
BjÖrk et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
EP1514876A3 (fr) Anticorps contre l'antigène de cellule souche prostatique
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
EP0753072A1 (fr) Marqueurs biologiques de l'hyperplasie benigne de la prostate
WO2003024191A3 (fr) Anticorps se fixant a l'antigene cytokeratine 8 associe au cancer et procedes d'utilisation correspondants
Strojan et al. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients
ATE283483T1 (de) Tumorenspezifisches p450 protein
AU7868300A (en) Prostate cancer marker proteins
AU4623599A (en) Method for diagnosing an adenocarcinoma or a benign prostate pathology
WO2004006860A3 (fr) Compositions permettant d'identifier et de cibles des cellules cancereuses exprimant une provasopressine et utilisations
Bussemakers Changes in gene expression and targets for therapy
Chu Prostate cancer-associated markers
WO2002023200A3 (fr) Biomarqueurs humains du cancer du sein
Lilja et al. Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer
AU4865997A (en) Monoclonal antibodies against a human act and serine protease complex
WO2003024302A3 (fr) Detection et traitement du cancer du sein